FDA Grants IDE Approval for Almac Diagnostic Services' CDx for Use in Cancer Drug Study

May 06, 2019

NEW YORK (GenomeWeb) – Turning Point Therapeutics and Almac Diagnostic Services today announced approval by the US Food and Drug Administration of an investigational device exemption for use of an Almac diagnostic assay to determine whether cancer patients are eligible to enroll in a Phase II clinical study.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Menu

FDA Grants IDE Approval for Almac Diagnostic Services' CDx for Use in Cancer Drug Study

To read the full story....

Breaking News

NICE Guidance Recommends Amgen's Blincyto for ALL Patients in Remission

Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug

Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer

AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan

Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program

Roche's Rozlytrek Nets Japanese Approval in NTRK-Positive Pan Cancer Indication

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

What's Popular?

Next-Generation Sequencing of Pediatric Cancer Patients Could Transform Treatment Paradigms

Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer

Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program

Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug

AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan

Sponsorships